Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) will participate in the H.C. Wainwright 24th Annual Global Investment Conference, with a pre-recorded presentation available on demand for attendees from September 12, 2022. The company is focused on developing rencofilstat, an AI-driven therapeutic for chronic liver diseases, including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Rencofilstat has received FDA Fast Track and Orphan Drug designations, demonstrating its potential in addressing liver disease and improving patient outcomes.

EDISON, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference.

Hepion’s pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, September 12, 2022, the presentation will also be available on the Company’s website at www.hepionpharma.com under “Events” in the “Investors” section.

About Hepion Pharmaceuticals

The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.

Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for rencofilstat to expand the company's footprint in

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com  

FAQ

What conference will Hepion Pharmaceuticals attend in September 2022?

Hepion Pharmaceuticals will participate in the H.C. Wainwright 24th Annual Global Investment Conference.

When will the Hepion Pharmaceuticals presentation be available?

The pre-recorded presentation will be available on demand starting September 12, 2022.

What is the focus of Hepion Pharmaceuticals' drug rencofilstat?

Rencofilstat is focused on treating chronic liver diseases, including NASH and HCC.

What designations has rencofilstat received from the FDA?

Rencofilstat has received Fast Track and Orphan Drug designations from the FDA.

How does Hepion Pharmaceuticals utilize AI in its drug development?

Hepion uses its AI platform, AI-POWR™, to optimize drug development and identify responsive NASH patients.